A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
World TB Day 2017
Recent News and Announcements
Médecins Sans Frontières (MSF), Partners In Health (PIH) and other leading medical organizations have launched a major clinical trial which seeks to revolutionize treatment for the toughest strains of tuberculosis (TB). The first patient started treatment in Georgia earlier this month. This phase III clinical trial is part of a UNITAID-funded transformative project called endTB, […]
In an open letter sent to Sequella on 21 February 2017, TB advocates called attention to the recent agreement between Johns Hopkins University and the Medicines Patent Pool regarding the rights to develop sutezolid in combination for TB, and urged Sequella to provide open access to all existing clinical data for sutezolid to facilitate and accelerate its further […]
On February 27, the WHO released its first Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics, which includes 12 families of bacteria that “pose the greatest threat to human health”. The WHO excludes M. tuberculosis from this “Priority Pathogens” list, and has subsequently sparked fierce controversy within the infectious disease […]
The Delhi High Court’s ruling in the recent landmark lawsuit that granted an 18-year old Indian girl with XDR-TB access to bedaquiline has led health advocates to seek inclusion of delamanid in the Indian government’s Revised National Tuberculosis Control Program. “It is time the government enforces public health safeguards in the patent law and licenses the drug […]
Two new drug therapies may have be able to cure all forms of tuberculosis, including the forms that are most difficult to treat. The treatments, called BPaMZ and BPaL, have the potential to make TB treatment simpler and more effective. BPaMZ involves taking four drugs once a day, and initial trial results suggest that it […]